Emerging role of GLP-1 receptor agonists in the treatment of obesity
Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity has increased dramatically in recent decades,...
Guardado en:
Autores principales: | Lisa M Neff, Robert F Kushner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ab3d151b2fa0441e8cc19b08cb63c808 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010) -
Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee W Chia, et al.
Publicado: (2009) -
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013) -
Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019) -
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)